非酒精性脂肪性肝病脂毒性多臂表型研究进展

doi:10.3969/j.issn.1672-5069.2018.02.001

Abstract

Zeng Minde. Mechanisms of lipotoxicity in pathogenesis of nonalcoholic fatty liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 153-156.

[1] Neuschwander-Tetri BA.Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis:the central role of nontriglyceride fatty acid metabolites. Hepatology,2010,52:774-788.
[2] Unger RH,Scherer PE.Gluttony,sloth and the metabolic syndrome:a roadmap to lipotoxicity. Trends Endocrinol Metab,2010,21:345-352.
[3] Ibrahim SH,Kohli R,Gores GJ.Mechanisms of lipotoxicity in NAFLD and clinical implications. J Pediatr Gastroenterol Nutr,2011,53:131-140.
[4] Fuchs M,Sanyal AJ.Lipotoxicity in NASH. J Hepatol,2012,56:291-293.
[5] Zambo V,Simon-Szabo L,Szelenyi P,et al.Lipotoxicity in the liver. World J Hepatol,2013,5:550-557.
[6] Mashek DG,Khan SA,Sathyanarayan A,et al.Hepatic lipid droplet biology:Getting to the root of fatty liver. Hepatology,2015,62:964-967.
[7] Welte MA.As the fat flies: The dynamic lipid droplets of Drosop-hila embryos. Biochim Biophys Acta,2015,1851:1156-1185.
[8] Welte MA.Expanding roles for lipid droplets. Curr Biol,2015,25:R470-481.
[9] Saponaro C,Gaggini M,Carli F,et al.The subtle balance between lipolysis and lipogenesis:A critical point in metabolic homeostasis. Nutrients,2015,7:9453-9474.
[10] Sanders FW,Griffin JL.De novo lipogenesis in the liver in health and disease:more than just a shunting yard for glucose. Biol Rev Camb Philos Soc,2016,91:452-468.
[11] Ress C,Kaser S.Mechanisms of intrahepatic triglyceride accumulation. World J Gastroenterol,2016,22:1664-1673.
[12] Berlanga A,Guiu-Jurado E,Porras JA,et al.Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol,2014,7:221-239.
[13] Gorden DL,Myers DS,Ivanova PT,et al.Biomarkers of NAFLD progression:a lipidomics approach to an epidemic. J Lipid Res,2015,56:722-736.
[14] 杨蕊旭,胡春秀,宓余强,等. 非酒精性脂肪性肝病患者血清脂质组学研究. 中华肝脏病杂志,2017,25:122-127.
[15] Garcia-Ruiz C,Morales A,Fernandez-Checa JC.Glycosphingolipids and cell death:one aim,many ways. Apoptosis,2015,20:607-620.
[16] Birkenfeld AL,Shulman GI.Nonalcoholic fatty liver disease,hepatic insulin resistance,and type 2 diabetes. Hepatology,2014,59:713-723.
[17] Loria P,Lonardo A,Anania F.Liver and diabetes. A vicious circle. Hepatol Res,2013,43:51-64.
[18] Pajvani UB,Accili D.The new biology of diabetes. Diabetologia,2015,58:2459-2468.
[19] Ogihara T,Mirmira RG.An islet in distress:beta cell failure in type 2 diabetes. J Diabetes Investig,2010,1:123-133.
[20] Gooding JR,Jensen MV,Newgard CB.Metabolomics applied to the pancreatic islet. Arch Biochem Biophys,2016,589:120-130.
[21] MacDonald MJ,Ade L,Ntambi JM,et al. Characterization of phospholipids in insulin secretory granules and mitochondria in pancreatic beta cells and their changes with glucose stimulation. J Biol Chem,2015,290:11075-11092.
[22] Rolo AP,Teodoro JS,Palmeira CM.Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med,2012,52:59-69.
[23] Mello T,Zanieri F,Ceni E,et al.Oxidative stress in the healthy and wounded hepatocyte:A cellular organelles perspective. Oxid Med Cell Longev,2016,2016:8327410.
[24] Di Meo S,Reed TT,Venditti P,et al.Role of ROS and RNS sources in physiological and pathological conditions. Oxid Med Cell Longev,2016,2016:1245049.
[25] Begriche K,Massart J,Robin MA,et al.Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology,2013,58:1497-1507.
[26] Win S,Than TA,Le BH,et al.Sab(Sh3bp5) dependence of JNK mediated inhibition of mitochondrial respiration in palmitic acid induced hepatocyte lipotoxicity. J Hepatol,2015,62:1367-1374.
[27] Frohman MA.Role of mitochondrial lipids in guiding fission and fusion. J Mol Med (Berl),2015,93:263-269.
[28] Dara L,Ji C,Kaplowitz N.The contribution of endoplasmic reticulum stress to liver diseases. Hepatology,2011,53:1752-1763.
[29] Leamy AK,Egnatchik RA,Shiota M,et al.Enhanced synthesis of saturated phospholipids is associated with ER stress and lipotoxicity in palmitate treated hepatic cells. J Lipid Res,2014,55:1478-1488.
[30] Egnatchik RA,Leamy AK,Jacobson DA,et al.ER calcium release promotes mitochondrial dysfunction and hepatic cell lipotoxicity in response to palmitate overload. Mol Metab,2014,3:544-553.
[31] Alisi A,Carsetti R,Nobili V.Pathogen-or damage-associated molecular patterns during nonalcoholic fatty liver disease development. Hepatology,2011,54:1500-1502.
[32] Farrell GC,van Rooyen D,Gan L,et al. NASH is an inflammatory disorder:Pathogenic,prognostic and therapeutic implications. Gut Liver,2012,6:149-171.
[33] Peverill W,Powell LW,Skoien R.Evolving concepts in the pathogenesis of NASH:beyond steatosis and inflammation. Int J Mol Sci,2014,15:8591-8638.
[34] Marra F,Lotersztajn S.Pathophysiology of NASH:perspectives for a targeted treatment. Curr Pharm Des,2013,19:5250-5269.
[35] Duwaerts CC,Maher JJ.Mechanisms of liver injury in non-alcoholic steatohepatitis. Curr Hepatol Rep,2014,13:119-129.
[36] Povero D,Feldstein AE.Novel molecular mechanisms in the development of non-alcoholic steatohepatitis. Diabetes Metab J,2016,40:1-11.
[37] Hirsova P,Gores GJ.Death receptor-mediated cell death and proinflammatory signaling in nonalcoholic steatohepatitis. Cell Mol Gastroenterol Hepatol,2015,1:17-27.
[38] Giles DA,Moreno-Fernandez ME,Divanovic S.IL-17 axis driven inflammation in non-alcoholic fatty liver disease progression. Curr Drug Targets,2015,16:1315-1323.
[39] Sharifnia T,Antoun J,Verriere TG,et al.Hepatic TLR4 signaling in obese NAFLD. Am J Physiol Gastrointest Liver Physiol,2015,309:G270-278.
[40] Liu XL,Ming YN,Zhang JY,et al.Gene-metabolite network analysis in different nonalcoholic fatty liver disease phenotypes. Exp Mol Med,2017,49:e283.
[41] Sui YH,Luo WJ,Xu QY,et al.Dietary saturated fatty acid and polyunsaturated fatty acid oppositely affect hepatic NOD-like receptor protein 3 inflammasome through regulating nuclear factor-kappa B activation. World J Gastroenterol,2016,22:2533-2544.
[42] Czaja MJ,Ding WX,Donohue TM,et al.Functions of autophagy in normal and diseased liver. Autophagy,2013,9:1131-1158.
[43] Schneider JL,Cuervo AM.Liver autophagy:much more than just taking out the trash. Nat Rev Gastroenterol Hepatol,2014,11:187-200.
[44] Rambold AS,Cohen S,Lippincott-Schwartz J.Fatty acid trafficking in starved cells:regulation by lipid droplet lipolysis,autophagy,and mitochondrial fusion dynamics. Dev Cell,2015,32:678-692.
[45] Wang K.Autophagy and apoptosis in liver injury. Cell Cycle,2015,14:1631-1642.

Mechanisms of lipotoxicity in pathogenesis of nonalcoholic fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Chen Shuai, Yang Changqing.. Pathogenesis and risk factors of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 761-764.
[2]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[3]	Zhong Yan, Su Shuting, Mi Yuqiang.. Treatment of patients with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 145-148.
[4]	Hu Hulan, Zhu Mengfei, Shi Junping.. Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 149-152.
[5]	Huang Faguang, Li Xiaocheng, Gong Jianping, et al.. Research on insulin resistance related protein molecules in human liver tissues by comprehensive gene expression profiling analysis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 872-876.
[6]	Pu Yonglan, Chen Yuanwen, Fan Jiangao.. Gluten intestinal disease and nonalcoholic fatty liver: One case report [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 981-982.
[7]	Cui Ruibing, Yan Ming.. Etiology of ascites:what’s going on [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 657-660.
[8]	Li Yue, Ding Huiguo.. Current diagnosis and treatment of chylous ascites [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 665-668.
[9]	Chi Zhaochun. Pathogenesis of nonalcoholic steatohepatitis and cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 166-169.
[10]	Xin Fengzhi, Cao Haixia, Fan Jiangao. Glucagon-like peptide-1 in melioration of non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 313-316.
[11]	Wang Qian,Guo Ping. Application of fibroscan and anthropometric parameters in diagnosis of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(6): 754-755.
[12]	Li Yan，Wang Caihua.. Hot spots in dietary therapy in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 529-531.
[13]	Pang Xiaoning，Liu Yanjun.. A comparative study of liraglutide,sitagliptin and pioglitazone in the treatment of patients with nonalcoholic fatty liver diseases and type 2 diabetes mellitus [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 604-605.
[14]	Wu Limeng，Zhao Jiufa.. Role of Treg and Th17 cells in the pathogenesis of hepatitis B-induced acute-on-chronic liver failure [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 639-642.
[15]	Guan Jun, Xu Ye. Risk factors of nonalcoholic fatty liver diseases in adolescents [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(3): 347-349.